TRANSCENTA-B (06628) announced at AACR 2025 a new type of antibody-drug conjugate (ADC) targeting FGFR2b, conjugated with a topoisomerase I inhibitor, showing encouraging anti-tumor activity in preclinical tumor models.

TRANSCENTA-B (06628) announced that the company will participate in the 2025 American Association for Cancer Research Annual Meeting (AAC...)

Zhitong FinanceApr 29 18:17 ET

Would Transcenta Holding (HKG:6628) Be Better Off With Less Debt?

Simply Wall StApr 29 02:20 ET

TRANSCENTA-B: 2024 ANNUAL REPORT

HKEXApr 22 04:37 ET · Announcements

TRANSCENTA-B (06628.HK) awarded 0.676 million shares as stock incentives.

Gelonghui, April 2nd丨TRANSCENTA-B (06628.HK) announced that the Board of Directors decided to grant 0.676 million shares of reward stock to 27 award recipients according to the stock incentive plan on April 2, 2025.

Gelonghui FinanceApr 2 05:58 ET

TRANSCENTA-B: SUPPLEMENTAL ANNOUNCEMENT

HKEXMar 30 19:20 ET · Announcements

Express News | Transcenta Holding Limited FY Revenue RMB 11.3 Million

ReutersMar 30 06:21 ET